All studies
Phase 3RecruitingInterventionalNCT07577856

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis (DUET ENCORE-UC)

78934804UCO3001: A Phase 3 Randomized, Double-blind, and Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  • Colitis, Ulcerative
I want to take partRefer a patient8 sites in India · 318 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Janssen Research & Development, LLC
Enrolment target
644
Started
23 May 2026
Main results due (estimated)
11 August 2028
Study ends (estimated)
16 October 2030
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Double (participant, investigator)
Sites
318 · 8 in India
First posted
11 May 2026
Registry updated
3 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion criteria:

* Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC.
* Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy
* An endoscopy subscore \>=2 as obtained during central review of the screening video endoscopy
* Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies

Exclusion criteria:

* Isolated proctitis (UC limited to the rectum only or to less than \[\<\] 20 centimeter \[cm\] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis
* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD
* Has a history of or ongoing chronic or recurrent infectious disease
* Has previously demonstrated inadequate initial response, loss of response, allergy, hypersensitivity or intolerance to guselkumab or to golimumab
* Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).

What participants receive

  • Experimental

    JNJ-78934804

    Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804

  • Active comparator

    Guselkumab

    Participants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804 · Drug: Guselkumab

Interventions

  • JNJ-78934804Drug

    Also known as JNJ-4804

    JNJ-78934804 will be administered subcutaneously.

  • GuselkumabDrug

    Also known as TREMFYA

    Guselkumab will be administered subcutaneously.

What the study measures

Primary outcomes

  1. Percentage of Participants in Clinical Remission at Week 48

    Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants with Endoscopic Improvement at Week 48

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week 48

  2. Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48

    Corticosteroid-free (90 day) clinical remission is defined as clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.

    Time frame: At Week 48

  3. Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Histologic remission is defined as an absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system.

    Time frame: At Week 48

  4. Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48

    Fatigue response is defined as a greater than or equal to (\>=) 7- point reduction in the patient-reported outcomes measurement information system (PROMIS) fatigue short form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).

    Time frame: At Week 48

  5. Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0

    Percentage of participants with a SF subscore of 0 or 1 and RB subscore of 0 at three assessment time points of Week 12, Week 24, and Week 48 will be reported.

    Time frame: At Weeks 12, 24, and 48

  6. Percentage of Participants in Abdominal Pain Remission at Week 48

    Percentage of participants in abdominal pain remission at week 48 will be reported.

    Time frame: At Week 48

  7. Change From Baseline in Abdominal Pain Score at Week 48

    Change from baseline in abdominal pain score based on abdominal pain-numerical rating scale (AP-NRS) will be reported. NRS is 11 point (0 to 10) scoring system used to evaluate abdominal pain. The score of 0 represents "no pain" and the score of 10 represents "pain as bad as you can imagine", with greater scores indicating greater pain severity and intensity.

    Time frame: Baseline and Week 48

  8. Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48

    IBDQ response is defined as improvement from baseline in the total IBDQ score of \>= 16 points. The IBDQ is a 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).

    Time frame: At Week 48

  9. Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48

    PROMIS 29 MCS response is defined as a \>= 7-point improvement from baseline in PROMIS 29 MCS response at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.

    Time frame: At Week 48

  10. Percentage of Participants in Clinical Remission at Week 12

    Clinical remission is defined as an SF subscore of 0 or 1, RB subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week 12

  11. Percentage of Participants with Endoscopic Improvement at Week 12

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week 12

  12. Percentage of Participants with Mayo SF/RB Response at Week 2

    Mayo SF/RB response is defined as a decrease from baseline in the sum of the SF and the RB subscores by \>=30 percent (%) and \>= 1 point, with either a \>= 1 point decrease from baseline in the RB subscore or an RB subscore of 0 or 1.

    Time frame: At Week 2

  13. Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to approximately 3 years

Who is running it

Lead sponsor
Janssen Research & Development, LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Janssen Research & Development, LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
78934804UCO3001
Other IDs
78934804UCO3001, 2026-525923-26-00
  • Janssen Research & Development, LLC Clinical Trial

    Study director

    Janssen Research & Development, LLC

Study sites(318)

  • Sushruta Multispecialty Hospital and Research Centre

    Hubli, India

    Recruiting

  • Asian Institute Of Gastroenterology

    Hyderabad, India

    Recruiting

  • S. R. Kalla Memorial General Hospital

    Jaipur, India

    Recruiting

  • Lisie Hospital

    Kochi, India

    Recruiting

  • P D Hinduja National Hospital and Medical Research Center

    Mumbai (ex Bombay), India

    Recruiting

  • Yashoda Super Speciality Hospitals

    Secunderabad, India

    Recruiting

  • SIDS Hospital & Research Centre

    Surat, India

    Recruiting

  • Gujarat Gastro and Vascular Hospital

    Surat, India

    Recruiting

  • Mayo Clinic

    Scottsdale, Arizona, United States

    Recruiting

  • GIA Sun City

    Sun City, Arizona, United States

    Recruiting

  • Clinnova Research

    Anaheim, California, United States

    Recruiting

  • Gastro SB Clinic

    Chula Vista, California, United States

    Recruiting

  • United Medical Doctors

    Los Alamitos, California, United States

    Recruiting

  • Medical Associates Research Group, Inc.

    San Diego, California, United States

    Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado, United States

    Recruiting

  • Florida Research Center Inc.

    Lakewood Rch, Florida, United States

    Recruiting

  • Sanchez Clinical Research, Inc

    Miami, Florida, United States

    Recruiting

  • Endoscopic Research Inc

    Orlando, Florida, United States

    Recruiting

  • GCP Clinical Research

    Tampa, Florida, United States

    Recruiting

  • Atlanta Gastroenterology Specialists

    Suwanee, Georgia, United States

    Recruiting

  • Tri-State Gastroenterology Assoc

    Crestview Hills, Kentucky, United States

    Recruiting

  • Gastroenterology Clinic of Acadiana

    Lafayette, Louisiana, United States

    Recruiting

  • GIA Metairie

    Metairie, Louisiana, United States

    Recruiting

  • GIA Kansas City

    Lee's Summit, Missouri, United States

    Recruiting

  • New York Gastroenterology Associates

    New York, New York, United States

    Recruiting

  • University of North Carolina Hospital

    Chapel Hill, North Carolina, United States

    Recruiting

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio, United States

    Recruiting

  • Digestive Disease Specialists Inc

    Oklahoma City, Oklahoma, United States

    Recruiting

  • The Oregon Clinic

    Portland, Oregon, United States

    Recruiting

  • Michigan Center of Medical Research

    Farmington Hill, Pennsylvania, United States

    Recruiting

  • Frontier Clinical Research

    Uniontown, Pennsylvania, United States

    Recruiting

  • Palmetto Primary and Specialty Care Physicians, Charleston

    Summerville, South Carolina, United States

    Recruiting

  • Gastro One

    Cordova, Tennessee, United States

    Recruiting

  • Southern Star Research Institute, LLC

    San Antonio, Texas, United States

    Recruiting

  • Tyler Research Institute, LLC

    Tyler, Texas, United States

    Recruiting

  • GIA Webster

    Webster, Texas, United States

    Recruiting

  • GIA Richmond

    Richmond, Virginia, United States

    Recruiting

  • GI Alliance Tacoma

    Tacoma, Washington, United States

    Recruiting

  • Instituto Medico De Alta Complejidad (IMAC)

    Buenos Aires, Argentina

    Recruiting

  • GEDYT

    Famailla, Argentina

    Recruiting

Showing 40 of 318 sites. 318 recruiting, 0 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Source: ClinicalTrials.gov record NCT07577856, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.